Intrasense — Regulatory Filings 2018

Nov 22, 2018

Press release Montpellier (France), November 22, 2018 - 5:45 pm CET

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions and Myrian® creator, announces the presentation of several innovative products based on Myrian® technology, with its partners 12 Sigma Technologies et Quantib, at RSNA 2018 (Radiological Society of North America), an international reference congress of radiology. Intrasense will also provide Myrian® as a pedagogical reference tool for the "Prostate MRI" workshop presented by internationally renowned professors.

Introducing Artificial Intelligence into clinical practice

During the RSNA - the largest radiology congress worldwide, bringing together in Chicago (USA) radiologists from 136 countries from November 25 to 30, 2018 -, Intrasense will present its innovative solutions and will welcome on its booth two of its partners, 12 Sigma Technologies and Quantib, using Artificial Intelligence in their clinical applications, developed with Intrasense technology Myrian® Studio on the Myrian® platform:

• σ-Discover Lung, an application developed by 12 Sigma Technologies for lung cancer detection, revolutionizing the market with its extraordinary thin segmentation and analysis of lung nodules.
• Quantib™ ND, a high-tech imaging application for neurology produced by Quantib, spin-off of Medical University of Rotterdam (Erasmus University Medical Center - Netherlands). Quantib™ ND integrates a variety of hightech MRI brain scan analysis.

Myrian® Studio, a springboard for innovation

During the RSNA, Intrasense encourages development of innovation in imaging, unveiling the winners for « Myrian® Studio Challenge » prize, rewarding and supporting startups and researchers working on particularly innovative projects. Its objective is to enable them to industrialize and commercialize their solution very quickly, with the support of Myrian®.

Myrian® used during a workshop dedicated to the reference method "PI-RADS 2"

This year, internationally renowned professors have once again chosen to use the Myrian® XP-Prostate software to train 1.000 radiologists in the MRI reference method PI-RADS 2 (Prostate Imaging Reporting and Data System).

The "MRI Prostate" workshop will enable to practice analysis using the PI-RADS 2, a world-reference methodology for MRI directly integrated in Myrian® XP-Prostate software.

This method optimizes patient management and follow-up: physicians can score the probability of the presence of a prostate cancer in patients, optimize recognition and differentiation from benign pathology.

"We are really honored that Myrian® has been selected, this year again, for this reference and large audience scientific workshop. Since its creation, Myrian® XP-Prostate integrates the PI-RADS scoring mechanism, providing instantaneous access to valuable information to clinicians." comments Frédéric HENAFF, Product Director at Intrasense.

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

More information on www.intrasense.fr.

Contacts

Intrasense Nicolas Reymond Chief Executive Officer Montpellier - FRANCE Tel: +334 67 130 130 investor@intrasense.fr

NewCap Investor Relations and Financial Communication Valentine Brouchot - Pierre Laurent Tel: +331 44 71 94 96 intrasense@newcap.eu